Abeona Therapeutics Inc (ABEO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) has a cash flow conversion efficiency ratio of -0.113x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.95 Million) by net assets ($159.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Abeona Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Abeona Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Abeona Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Abeona Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abeona Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hung Ching Development & Construction Co Ltd
TW:2527
|
-0.026x |
|
SDT Uzay ve Savunma Teknolojileri A.S.
IS:SDTTR
|
0.063x |
|
Cartesian Growth Corporation III Class A Ordinary Shares
NASDAQ:CGCT
|
-0.001x |
|
MCNEX Co. Ltd
KQ:097520
|
0.085x |
|
American Integrity Insurance Group, Inc.
NYSE:AII
|
0.149x |
|
ZKH Group Limited
NYSE:ZKH
|
0.079x |
|
UD Electronic
TWO:3689
|
0.126x |
|
Amazing Microelectronic
TWO:6411
|
0.030x |
Annual Cash Flow Conversion Efficiency for Abeona Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Abeona Therapeutics Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see ABEO market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $159.22 Million | $-76.33 Million | -0.479x | +62.32% |
| 2024-12-31 | $44.03 Million | $-56.02 Million | -1.272x | +49.04% |
| 2023-12-31 | $14.83 Million | $-37.01 Million | -2.496x | -53.63% |
| 2022-12-31 | $26.76 Million | $-43.48 Million | -1.625x | -4.84% |
| 2021-12-31 | $42.37 Million | $-65.67 Million | -1.550x | -353.87% |
| 2020-12-31 | $102.55 Million | $-35.02 Million | -0.341x | +3.01% |
| 2019-12-31 | $178.43 Million | $-62.82 Million | -0.352x | -20.67% |
| 2018-12-31 | $134.04 Million | $-39.11 Million | -0.292x | -116.40% |
| 2017-12-31 | $170.10 Million | $-22.93 Million | -0.135x | -2.67% |
| 2016-12-31 | $99.10 Million | $-13.01 Million | -0.131x | +14.67% |
| 2015-12-31 | $67.72 Million | $-10.42 Million | -0.154x | +53.99% |
| 2014-12-31 | $4.82 Million | $-1.61 Million | -0.335x | -494272.28% |
| 2013-12-31 | $-14.78 Million | $1.00K | 0.000x | -100.03% |
| 2012-12-31 | $-17.08 Million | $-3.96 Million | 0.232x | -46.41% |
| 2011-12-31 | $-17.61 Million | $-7.61 Million | 0.432x | +31.01% |
| 2010-12-31 | $-20.80 Million | $-6.86 Million | 0.330x | +296.06% |
| 2009-12-31 | $-26.99 Million | $-2.25 Million | 0.083x | -85.80% |
| 2008-12-31 | $-11.19 Million | $-6.56 Million | 0.586x | -91.75% |
| 2007-12-31 | $681.00K | $4.84 Million | 7.112x | +3491.03% |
| 2006-12-31 | $-9.89 Million | $-1.96 Million | 0.198x | -88.51% |
| 2005-12-31 | $-4.24 Million | $-7.30 Million | 1.723x | +26.45% |
| 2004-12-31 | $-6.66 Million | $-9.08 Million | 1.363x | +24.75% |
| 2003-12-31 | $-5.83 Million | $-6.36 Million | 1.092x | +106.21% |
| 2002-12-31 | $489.00K | $-8.60 Million | -17.577x | -2926.58% |
| 2001-12-31 | $9.08 Million | $-5.27 Million | -0.581x | -101.19% |
| 2000-12-31 | $15.00 Million | $-4.33 Million | -0.289x | +67.98% |
| 1999-12-31 | $3.60 Million | $-3.25 Million | -0.901x | +49.30% |
| 1998-12-31 | $1.80 Million | $-3.20 Million | -1.778x | +70.65% |
| 1997-12-31 | $599.00K | $-3.63 Million | -6.057x | -821.68% |
| 1996-12-31 | $4.06 Million | $-2.67 Million | -0.657x | -268.38% |
| 1995-12-31 | $1.69 Million | $658.00K | 0.390x | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more